Biolase (BIOL) Tops Q3 EPS by 1c

Biolase (NASDAQ: BIOL) reported Q3 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $8.78 million.

GUIDANCE:

Biolase sees Q4 2021 revenue of $10.2 million, versus the consensus of $10.6 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c